Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
normal immunoglobulin, Quantity: 3 g
CSL Behring Australia Pty Ltd
normal immunoglobulin
Injection, solution
Excipient Ingredients: human immunoglobulin A; maltose
Intravenous Infusion
50 mL
(S1) This Schedule is intentionally blank
Intragam P is indicated for replacement IgG therapy in: * primary immunodeficiency (PID); * myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; * congenital or acquired immune deficiency syndrome with with recurrent infections; * congenital or acquired immune deficiency syndrome with recurrent infections. Intragam P is indicated for immunomodulatory therapy in: * Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; * allogeneic bone marrow transplantation; * Kawasaki disease; * Guillain-Barre Syndrome (GBS).
Visual Identification: A clear or slightly opalescent and colourless or pale yellow liquid.; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius
Licence status A
2014-01-08